GC Biopharma 和 Novelty Nobility 合作开发基于抗体的蛋白质疗法治疗地理萎缩。 GC Biopharma and Novelty Nobility partner on antibody-based protein therapeutics for geographic atrophy.

美国GC Biopharma和Novelty Nobility已经建立了合作伙伴关系,研究和开发地理缩 (GA) 的新疗法,这是一个严重的与年龄相关的斑点退化形式,影响约150万美国人. GC Biopharma and Novelty Nobility have formed a partnership to research and develop new treatments for geographic atrophy (GA), a serious form of age-related macular degeneration affecting about 1.5 million Americans. 他们的合作将集中在制造基于抗体的蛋白质疗法,利用新贵族在视网膜疾病治疗方面的专业知识和GC Biopharma在蛋白质疗法的优势. Their collaboration will focus on creating antibody-based protein therapeutics, leveraging Novelty Nobility's expertise in retinal disease treatments and GC Biopharma's strengths in protein therapeutics. 目标是提高治疗效果和病人的安全性。 The goal is to enhance treatment efficacy and safety for GA patients.